The "In Vivo" Frontier: Is 2026 the End of the "Clean Room" Requirement?
A major shift in the 2026 global industry is the record-breaking interest in "In Vivo CAR-T" platforms. This year, to cater to the need for faster treatment, the Cell Expansion Market is pivoting toward technologies that allow cells to be "reprogrammed" directly inside the patient's body, reducing the need for massive ex vivo expansion facilities. This level of "In-Body Manufacturing" is the...
0 Σχόλια 0 Μοιράστηκε 14 Views 0 Προεπισκόπηση